Tag: #clinicaltrials

Interim phase 3: Sacituzumab tirumotecan plus pembrolizumab improves PFS in PD-L1–positive advanced NSCLC

Interim phase 3 data: adding sacituzumab tirumotecan to pembrolizumab improved progression-free survival versus pembrolizumab alone in PD‑L1+ advanced NSCLC; OS immature, toxicity higher.

$MRK, #lungcancer, #pembrolizumab, #sacituzumabtirumotecan, #clinicaltrials

Tirzepatide shows broader heart-and-kidney edge over dulaglutide in diabetes trial analysis

A post hoc look at the 13,000-patient SURPASS-CVOT trial finds fewer combined heart and kidney events with tirzepatide than dulaglutide.

#diabetes, #cardiology, #glp1, #kidneydisease, #clinicaltrials

Finerenone Cuts Proteinuria in Type 1 Diabetes Kidney Disease Trial, but Long-Term Benefit Unproven

A phase 3 trial found finerenone lowered urine protein in adults with type 1 diabetes and CKD—raising hopes, but leaving outcome questions.

#diabetes, #kidneydisease, #clinicaltrials, #finerenone, #nephrology

Lilly’s daily GLP-1 pill beats Novo’s oral semaglutide in diabetes trial, but side effects drive more dropouts

A Phase 3 head-to-head study finds Lilly’s orforglipron lowered A1c and weight more than Rybelsus, with higher quit rates.

#diabetes, #glp1, #weightloss, #pharma, #clinicaltrials